A Randomized, Open-Label, Controlled, Multicenter, Phase III Clinical Study to Compare the Efficacy and Safety of HLX10 (Anti-PD-1 Antibody) in Combination With HLX04 (Anti-VEGF Antibody) Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)
Latest Information Update: 17 May 2022
At a glance
- Drugs Bevacizumab (Primary) ; Serplulimab (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Registrational; Therapeutic Use
- Sponsors Shanghai Henlius Biotech
- 22 Mar 2021 Planned initiation date changed from 15 Nov 2020 to 15 Nov 2021.
- 13 Jul 2020 New trial record